-DOCSTART- -X- O
Traditionally -X- _ O
, -X- _ O
vaccines -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
by -X- _ O
cultivating -X- _ O
infectious -X- _ O
agents -X- _ O
and -X- _ O
isolating -X- _ O
the -X- _ O
inactivated -X- _ O
whole -X- _ O
pathogen -X- _ O
or -X- _ O
some -X- _ O
of -X- _ O
its -X- _ O
purified -X- _ O
components. -X- _ O
20 -X- _ O
years -X- _ O
ago -X- _ O
, -X- _ O
reverse -X- _ O
vaccinology -X- _ O
enabled -X- _ O
vaccine -X- _ O
discovery -X- _ O
and -X- _ O
design -X- _ O
based -X- _ O
on -X- _ O
information -X- _ O
deriving -X- _ O
from -X- _ O
the -X- _ O
sequence -X- _ O
of -X- _ O
microbial -X- _ O
genomes -X- _ O
rather -X- _ O
than -X- _ O
via -X- _ O
the -X- _ O
growth -X- _ O
of -X- _ O
pathogens. -X- _ O
Today -X- _ O
, -X- _ O
the -X- _ O
high -X- _ B-Outcome
throughput -X- _ I-Outcome
discovery -X- _ I-Outcome
of -X- _ I-Outcome
protective -X- _ I-Outcome
human -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ O
sequencing -X- _ B-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
B -X- _ I-Outcome
cell -X- _ I-Outcome
repertoire -X- _ I-Outcome
, -X- _ O
and -X- _ O
the -X- _ O
increasing -X- _ B-Outcome
structural -X- _ I-Outcome
characterization -X- _ I-Outcome
of -X- _ I-Outcome
protective -X- _ I-Outcome
antigens -X- _ I-Outcome
and -X- _ I-Outcome
epitopes -X- _ I-Outcome
provide -X- _ O
the -X- _ O
molecular -X- _ O
and -X- _ O
mechanistic -X- _ O
understanding -X- _ O
to -X- _ O
drive -X- _ O
the -X- _ O
discovery -X- _ O
of -X- _ O
novel -X- _ O
vaccines -X- _ O
that -X- _ O
were -X- _ O
previously -X- _ O
impossible. -X- _ O
We -X- _ O
are -X- _ O
entering -X- _ O
a -X- _ O
“reverse -X- _ B-Intervention
vaccinology -X- _ I-Intervention
2.0” -X- _ I-Intervention
era -X- _ O
. -X- _ O

